T7741 |
DS-1001b
|
1898207-64-1
|
98%
|
|
DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)
|
T16161 |
Mutant IDH1 inhibitor
|
1429180-08-4
|
98%
|
|
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
|
T7307 |
Vorasidenib
|
1644545-52-7
|
98%
|
|
Vorasidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)
|
T1809 |
AGI-6780
|
1432660-47-3
|
98%
|
|
AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant.
|
T2043 |
Mutant IDH1-IN-1
|
1355326-21-4
|
98%
|
|
Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.
|
T12128 |
Mutant IDH1-IN-2
|
1429176-69-1
|
98%
|
|
Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor
|
T2104 |
AGI-5198
|
1355326-35-0
|
98%
|
|
AGI-5198 is a highly effective and specific inhibitor of IDH1 R132H/R132C mutants (IC50: 0.07/0.16 μM).
|
T16384 |
Olutasidenib
|
1887014-12-1
|
98%
|
|
Olutasidenib is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain pen...
|
TQ0042 |
BAY-1436032
|
1803274-65-8
|
98%
|
|
BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1).
|
T3617 |
Ivosidenib
|
1448347-49-6
|
98%
|
|
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a...
|
T2346 |
Enasidenib
|
1446502-11-9
|
98%
|
|
Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineopl...
|